Inclusion Criteria:

- Have a histologically or cytologically confirmed diagnosis of a locally advanced or
metastatic carcinoma. (Patients may have either measurable or nonmeasurable
disease.)

- Be ≥18 years old.

- Must not be eligible for therapy of higher curative potential.

- Have a Karnofsky Performance Status (KPS) of ≥70%.

- Have an estimated life expectancy of ≥12 weeks.

- Be male or non-pregnant, non-lactating female patients. Patients who are fertile
agree to use an effective barrier method of birth control (e.g., latex condom,
diaphragm, or cervical cap) to avoid pregnancy.

- Have a negative serum or urine pregnancy test within 7 days prior to the first dose
of study drug (if patient is a female of childbearing potential).

- Sign a written informed consent document.

- Have adequate organ function as determined per protocol defined laboratory value

Exclusion Criteria:

- Have received previous treatment with ARQ 501.

- Have an active, uncontrolled systemic infection considered opportunistic, life
threatening, or clinically significant at the time of treatment.

- Are pregnant or lactating.

- Have a psychiatric disorder(s) that would interfere with consent, study
participation, or follow-up.

- Have received any chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major
surgery, or irradiation, whether conventional or investigational, within 2 weeks of
treatment in this study.

- Have not recovered from acute toxicity of all previous therapy prior to enrollment.

- Have any other severe concurrent disease, which, in the judgment of the investigator,
would make the patient inappropriate for entry into this study.

- Have symptomatic or untreated central nervous system (CNS) metastases.

- Have a known severe hypersensitivity to docetaxel or drugs formulated with
polysorbate 80.